Promoter hypermethylation in tumour suppressor genes and response to interleukin-2 treatment in bladder cancer: A pilot study

Journal of Cancer Research and Clinical Oncology

Volumn 136, Issue 6, 2010, Pages 847-854

  Jarmalaite, Sonata ^a   Andrekute, Rasa ^a   Scesnaite, Asta ^a   Suziedelis, Kestutis ^a   Husgafvel Pursiainen, Kirsti ^b   Jankevicius, Feliksas ^a  

^a VILNIUS UNIVERSITY   (Lithuania)

^b FINNISH INSTITUTE OF OCCUPATIONAL HEALTH   (Finland)

Author keywords

Bladder cancer; Interleukin 2; P16 gene; Promoter hypermethylation; Tumour suppressor genes

Indexed keywords

ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE; DEATH ASSOCIATED PROTEIN KINASE; DEATH-ASSOCIATED PROTEIN KINASE; INTERLEUKIN 2; RASSF1 PROTEIN, HUMAN; RETINOIC ACID RECEPTOR; RETINOIC ACID RECEPTOR BETA; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; ARTICLE; BLADDER TUMOR; CLINICAL TRIAL; CYSTOSCOPY; DNA METHYLATION; DRUG EFFECT; FEMALE; GENETICS; HUMAN; MALE; MIDDLE AGED; MUTATION; PILOT STUDY; POLYMERASE CHAIN REACTION; PROMOTER REGION; PROSPECTIVE STUDY; SINGLE STRAND CONFORMATION POLYMORPHISM; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; APOPTOSIS REGULATORY PROTEINS; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASES; CYSTOSCOPY; DNA METHYLATION; FEMALE; GENES, P16; GENES, P53; GENES, TUMOR SUPPRESSOR; HUMANS; INTERLEUKIN-2; MALE; MIDDLE AGED; MUTATION; PILOT PROJECTS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROMOTER REGIONS, GENETIC; PROSPECTIVE STUDIES; RECEPTORS, RETINOIC ACID; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEINS; URINARY BLADDER NEOPLASMS;

EID: 77951640256     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-009-0725-y     Document Type: Article

References (34)

1. Amling CL (2001) Diagnosis and management of superWcial bladder cancer. Curr Probl Cancer 25(4):219-278
2. Bakkar AA, Wallerand H, Radvanyi F et al (2003) FGFR3 and TP53 gene mutations deWne two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res 63(23):8108-8112
3. Bubeník J (2004) Interleukin-2 therapy of cancer. Folia Biol (Praha) 50(3-4):120-130
4. Bubeník J, Perlmann P, Indrova M, Simova J, Jandlova T, Neuwirt J (1983) Growth inhibition of an MC-induced mouse sarcoma by TCGF (IL 2)-containing preparations. Preliminary report. Cancer Immunol Immunother 14(3):205-206
5. Den Otter W, Dobrowolski Z, Bugajski A (1998) Intravesical interleukin-2 in T1 papillary bladder carcinoma: regression of marker lesion in 8 of 10 patients. J Urol 159(4):1183-1186
6. Dhawan D, Hamdy FC, Rehman I et al (2006) Evidence for the early onset of aberrant promoter methylation in urothelial carcinoma. J Pathol 209:336-343
7. Dranoff G (2004) Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 4(1):11-22
8. Esteller M (2003) Relevance of DNA methylation in the management of cancer. Lancet Oncol 4(6):351-358
9. Esteller M, Garcia-Foncillas J, Andion E et al (2000a) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343(19):1350-1354
10. Esteller M, Tortola S, Toyota M, Capella G, Peinado MA, Baylin SB, Herman JG (2000b) Hypermethylation-associated inactivation of p14(ARF) is independent of p16(INK4a) methylation and p53 mutational status. Cancer Res 60(1):129-133
11. Fischer JR, Ohnmacht U, Rieger N, Zemaitis M, Stoffregen C, Manegold C, Lahm H (2007) Prognostic significance of RASSF1A promoter methylation on survival of non-small cell lung cancer patients treated with gemcitabine. Lung Cancer 56(1):115-123
12. Friedrich MG, Chandrasoma S, Siegmund KD et al (2005) Prognostic relevance of methylation markers in patients with non-muscle invasive bladder carcinoma. Eur J Cancer 41:2769-2778
13. Gaffen SL, Liu KD (2004) Overview of interleukin-2 function, production and clinical applications. Cytokine 28(3):109-123
14. Grasso M, Torelli F, Scannapieco G, Franzoso F, Lania C (2001) Neoadjuvant treatment with intravesical interleukin-2 for recurrent superWcial transitional bladder carcinoma Ta-T1/G1-2. J Immunother 24(2):184-187
15. Grossman HB, Liebert M, Antelo M, Dinney CP, Hu SX, Palmer JL, Benedict WF (1998) p53 and RB expression predict progression in T1 bladder cancer. Clin Cancer Res 4(4):829-834
16. Herman JG, Baylin SB (2003) Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349(21):2042-2054
17. Herman JG, GraV JR, Myöhänen S, Nelkin BD, Baylin SB (1996) Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93(18):9821-9826
18. Holmila R, Husgafvel-Pursiainen K (2006) Analysis of TP53 gene mutations in human lung cancer: comparison of capillary electrophoresis single strand conformation polymorphism assay with denaturing gradient gel electrophoresis and direct sequencing. Cancer Detect Prev 30(1):1-6
19. Hoque MO, Begum S, Topalogu O et al (2006) Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. J Natl Cancer Inst 98(14):996-1004
20. IUAC (2002) IUAC TNM classification of malignant tumors, 6th edn. John Wiley and Sons, New York
21. Jankevicius F, Goebell P, Kushima M, Schulz WA, Ackermann R, Schmitz-Dräger BJ (2002) p21 and p53 Immunostaining and survival following systemic chemotherapy for urothelial cancer. Urol Int 69(3):174-180
22. Jarmalaite S, Jankevicius F, Kurgonaite K, Suziedelis K, Mutanen P, Husgafvel-Pursiainen K (2008) Promoter hypermethylation in tumour suppressor genes shows association with stage, grade and invasiveness of bladder cancer. Oncology 75(3-4):145-151
23. Josephson DY, Pasin E, Stein JP (2006) SuperWcial bladder cancer: part 1. Update on etiology, classification and natural history. Expert Rev Anticancer Ther 6(12):1723-1734
24. Kawamoto K, Enokida H, Gotanda T et al (2006) p16INK4a and p14ARF and methylation as a potential biomarker for human bladder cancer. Biochem Biophys Res Commun 339(3):790-796
25. Kirkali Z, Chan T, Manoharan M et al (2005) Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 66(6 Suppl 1):4-34
26. Knowles MA (2001) What we could do now: molecular pathology of bladder cancer. Mol Pathol 54(4):215-221
27. MostoW FK, Sobin LH, Torlini H (1973) Histological typing of urinary bladder tumors. In: International histological classification of tumors, No 10. World Health Organization, Geneva
28. Pyrhönen SO (2004) Systemic therapy in metastatic renal cell carcinoma. Scand J Surg 93(2):156-161
29. Ramirez JL, Rosell R, Taron M et al (2005) 14-3-3sigma methylation in pretreatment serum circulating DNA of cisplatin-plus-gemcitabine-treated advanced non-small-cell lung cancer patients predicts survival: The Spanish Lung Cancer Group. J Clin Oncol 23(36):9105-9112
30. Reu FJ, Leaman DW, Maitra RR et al (2006) Expression of RASSF1A, an epigenetically silenced tumour suppressor, overcomes resistance to apoptosis induction by interferons. Cancer Res 66(5):2785-2793
31. Schulz WA (2006) Understanding urothelial carcinoma through cancer pathways. Int J Cancer 119(7):1513-1518
32. Tada Y, Wada M, Taguchi K et al (2002) The association of Deathassociated Protein Kinase hypermethylation with early recurrence in superWcial bladder cancers. Cancer Res 62:4048-4053
33. Veltri RW, Makarov DV (2006) Nucleic acid-based marker approaches to urologic cancers. Urol Oncol 24(6):510-527
34. Widschwendter M, Siegmund KD, Müller HM et al (2004) Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res 64(11):3807-3813